Listed by the USPTO as AULAKH, CHARANJIT
Tech Center 1600 • Art Units: 1621 1625 1629 1652
This examiner grants 81% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17919650 | TARGETING THE PALMOTYLATION/DEPALMOTYLATION CYCLE TO TREAT INFLAMMATORY DISEASES | Final Rejection | CORNELL UNIVERSITY |
| 18279290 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Final Rejection | Mindset Pharma Inc. |
| 18279903 | PROCESS FOR PREPARING A MELAMINE CONDENSATION PRODUCT | Final Rejection | BASF SE |
| 18781405 | METAL-ASSISTED DELAYED FLUORESCENT EMITTERS CONTAINING TRIDENTATE LIGANDS | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18790038 | COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT | Non-Final OA | President and Fellows of Harvard College |
| 18820706 | FASORACETAM CRYSTALLINE FORMS | Non-Final OA | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 18843651 | METHODS OF TREATING CANCER WITH IAP ANTAGONIST COMPOUNDS AND COMBINATION THERAPIES | Non-Final OA | Board of Regents, The University of Texas System |
| 18716052 | GLUCOCORTICOID RECEPTOR BLOCKADE WITH MIFEPRISTONE TO SENSITIZE PANCREATIC CANCER TO IMMUNOTHERAPY | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18839131 | SMALL MOLECULES TARGETTING EIF3E TO INHIBIT TUMOR GROWTH PROGRESSION, AND METASTASIS | Non-Final OA | The Regents of the University of Colorado, A Body Corporate |
| 18171735 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | Non-Final OA | ASTRAZENECA AB |
| 18719945 | AQUEOUS COSMETIC COMPOSITION COMPRISING VANILLIN OR ONE OF ITS DERIVATIVES, A SPECIFIC SEQUESTERING AGENT, AND POSSIBLY AT LEAST ONE ADDITIONAL ANTIMICROBIAL | Final Rejection | L'OREAL |
| 18293923 | INTEGRATED PROCESS FOR 5-(METHOXYCARBONYL)FURAN-2-CARBOXYLIC ACID (MCFC) | Final Rejection | Eastman Chemical Company |
| 18504198 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | Final Rejection | BRISTOL-MYERS SQUIBB COMPANY |
| 18695585 | METHOD FOR PRODUCING ALKYLFURANCARBOXYLIC ACID ESTER | Non-Final OA | Mitsubishi Gas Chemical Company, Inc. |
| 18871262 | BICYCLIC AMINE CDK12 INHIBITORS | Non-Final OA | Incyte Corporation |
| 18939388 | DERIVATIVES OF AN FGFR INHIBITOR | Non-Final OA | Incyte Corporation |
| 18678931 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Final Rejection | INCYTE CORPORATION |
| 18792897 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Non-Final OA | UNIVERSAL DISPLAY CORPORATION |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy80.8% of resolved applications examined by Charanjit Aulakh were allowed (1,798 resolved cases), compared with 46.7% across Art Unit 1621 over the last five years.
This examiner's interview lift is -14.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Charanjit Aulakh took 755 days on average from filing to allowance.
Charanjit Aulakh examines applications in Art Unit 1621 in Tech Center 1600 (Biotechnology & Pharmaceuticals).